DUBLIN – For Graves’ Disease Awareness Month in July, Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with world-renowned track star and three-time Olympic gold medalist Gail Devers, who has been living with Graves’ disease and symptoms of Thyroid Eye Disease (TED) for more than 30 years. Horizon and Devers...
Latest News
BETHESDA, Md.– Gain Therapeutics, Inc., a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators that demonstrate therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage...
Bethesda, Md. — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, announced financial results for the full year ended December 31, 2022, and highlighted recent corporate progress. “We have made significant progress across our pipeline this...
Mechelen, Belgium – Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th American Society of Hematology (ASH) Annual Meeting. “The new and updated results from the...
ZUG, Switzerland — Galderma today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis. Nemolizumab is a first-in-class investigational monoclonal antibody specifically designed to inhibit...
KENSINGTON, Md. — Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, announces encouraging data with orally available small molecule GAL-201, showing its neuroprotective and symptomatic alleviation potential in...
– AM-001 Study represents a pivotal milestone in Galmed’s transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development – Aramchol Meglumine, a New Chemical Entity (NCE) protected by patents until 2035, is being developed both as a standalone agent and in novel drug combinations...
Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment leads to significant inhibition (2-fold, p<0.05) of TGFβ-induced hepatic fibrosis pathways while upregulating peroxisome proliferator activated receptor (PPAR) signaling Aramchol’s effect in the prevention and treatment of biliary and hepatic...
LONDON, UK — Ayrmid Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., a cell therapy pioneer working to turn cells into powerful therapeutics, announced positive interim study results for omidubicel, a stem cell transplant therapy, in treating Severe Aplastic Anemia (SAA). The findings were shared by...
LONDON – GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer, today announced that it has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered,...